Table of Content


Winter 2019, Vol. 27 No. 4

Hong Kong J. Dermatol. Venereol. (2019) 27, 165-169

Original Article

An 11-year single centre experience with etanercept use in the treatment of moderate-to-severe psoriasis: a retrospective report


CE Lim 林恩恩, HH Oon 溫惠文, WS Chong 張維盛


Introduction: Biologics have significantly improved patient outcomes in psoriasis. This study describes our clinical experience using etanercept for the treatment of moderate-to-severe psoriasis. Methods: We conducted a retrospective analysis of patients with moderate-to-severe psoriasis started on etanercept from December 2004 to May 2016 at the National Skin Centre, Singapore. The primary measure of clinical response was 75% or greater improvement in percentage of affected body surface area (BSA) following 12 weeks of treatment. Results: Twelve out of twenty-three patients (52%) achieved at least 75% improvement in the percentage of BSA after 12 weeks of treatment. Etanercept was generally well tolerated. Conclusion: Etanercept for the treatment of psoriasis showed improvement in disease severity after 12 weeks in a substantial number of patients.


Keywords: Efficacy, etanercept, psoriasis, safety

關鍵詞: 功效、依那西普、銀屑病、安全